News Release 

DARPA selects Continuity Pharma, funds continuous manufacturing technology

Purdue University

Grant Announcement

The COVID-19 pandemic has created supply chain gaps in critical drug products, especially those needed for the most critical patients in intensive care units across the country.

DARPA (Defense Advanced Research Project Agency) has selected Continuity Pharma, a Purdue University-affiliated company, to develop continuous manufacturing technology. The company was selected for a $1.5 million grant.

DARPA has established a competitive review process, awarding grant funding to companies presenting advanced manufacturing technologies.

Continuity Pharma's mission is to apply novel continuous manufacturing capabilities to reshore generic drug products to the U.S., with specific focus on drugs in short supply.

"We are thrilled to be selected by DARPA to further our development efforts," said David Thompson, a Purdue professor of organic chemistry and co-founder and chief scientific officer at Continuity. "We are one step closer to ensuring the availability of essential medicines to patients in need. It is an exciting time for Continuity Pharma."

Grant specifics include development funding over the next 24 months, with additional funding for commercialization in the subsequent 12 months. Focus areas include capabilities for multiple API manufacturing in the Integrated Continuous Manufacturing System, with demonstrated efficiencies for rapid changeover and manufacturing efficiencies.

Continuity Pharma leaders are working with Purdue Research Foundation officials to secure additional lab space in Purdue Research Park in West Lafayette.

###

About Continuity Pharma

Continuity Pharma was formed with the mission to ensure a consistent supply of high-quality essential medicines for patients in need. The company accomplishes this by applying analytical and process design expertise to create modular and portable continuous manufacturing systems for synthesizing essential generic medicines. Using high throughput methodologies, they identify the ideal reaction conditions for preparing the active pharmaceutical ingredients (API) to be manufactured efficiently in continuous flow. The result is a high yield of medical-grade API with the least toxic waste and the best opportunity for production on scale. For additional information or questions, contact the company at contact@continuitypharma.com or call 812-805-0038.

About Purdue Research Foundation

The Purdue Research Foundation is a private, nonprofit foundation created to advance the mission of Purdue University. Established in 1930, the foundation accepts gifts; administers trusts; funds scholarships and grants; acquires property; protects Purdue's intellectual property; and promotes entrepreneurial activities on behalf of Purdue. The foundation manages the Purdue Foundry, Purdue Office of Technology Commercialization, Purdue Research Park, Purdue Technology Centers and University Development Office. In 2020, the IPWatchdog Institute ranked Purdue third nationally in startup creation and in the top 20 for patents. The foundation received the 2019 Innovation and Economic Prosperity Universities Award for Place from the Association of Public and Land-grant Universities. For more information on licensing a Purdue innovation, contact the Purdue Office of Technology Commercialization at otcip@prf.org. For more information about involvement and investment opportunities in startups based on a Purdue innovation, contact the Purdue Foundry at foundry@prf.org.

About Purdue University

Purdue University is a top public research institution developing practical solutions to today's toughest challenges. Ranked the No. 5 Most Innovative University in the United States by U.S. News & World Report, Purdue delivers world-changing research and out-of-this-world discovery. Committed to hands-on and online, real-world learning, Purdue offers a transformative education to all. Committed to affordability and accessibility, Purdue has frozen tuition and most fees at 2012-13 levels, enabling more students than ever to graduate debt-free. See how Purdue never stops in the persistent pursuit of the next giant leap at purdue.edu.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.